INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the third leading cause of cancer death world. In 2016, approximately 70,820 new cases and 26,020 CRC-related deaths were estimated in United States \[[@R1]\]. In China, the incidence of CRC has been increasing in recent years as living conditions improve and eating habits change. Surgical resection remains the only curative treatment opinion for CRC \[[@R2]\].

There are many known risk factors for predicting survival after surgical resection, including marital status, age, lymph node status, systemic inflammation, et al. \[[@R3]--[@R6]\]. Among them, the most significant risk factor is tumor-node-metastasis (TNM) staging. However, CRC is a heterogeneous disease, the current staging system is not precise for predicting patient outcomes because the prognosis varies even in patients with the same disease stage. Additional parameters need to be defined to better identify prognostic factors for patients, to allow tailored therapies \[[@R7]\].

Serum bilirubin, regarding as end product of heme metabolism, has been considered to have no physiological function. However, in recent years, some experimental and clinical researches have demonstrated that serum bilirubin has several protective effects, including potent antioxidant, anti-inflammatory and anticancer activities \[[@R8]--[@R10]\]. The inverse association between bilirubin and cancer risk has been observed in breast cancer \[[@R11]\], lung cancer \[[@R12]\] and colorectal cancer \[[@R10], [@R13]\]. Elevated serum bilirubin levels also are associated with improved survival in patients with curatively resected non-small-cell lung cancer \[[@R14]\]. Patients of breast cancer with higher total bilirubin level had a nearly 40% reduction in the risk of death \[[@R15]\]. Conversely, severe jaundice decreases long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma \[[@R16]\]. Increased serum direct bilirubin level was associated with lymph node metastasis and poor prognosis in rectal cancer patients \[[@R8]\], however, in their study, only patients with rectal cancer were included, the primary endpoint only included the overall survival (OS), and patients with stage IV disease also included.

This study aimed to assess the ability of serum bilirubin level to predict survival outcome in patients with CRC after radical resection. There are many studies in which the development of nomograms leads to a successful application for oncology prognostics. Nomograms for predicting follow-up outcome for CRC are scarce \[[@R6]\]. We further develop nomograms to investigate the prognostic role of serum bilirubin level in patients with CRC.

RESULTS {#s2}
=======

Patients' baseline characteristics {#s2_1}
----------------------------------

A total of 986 patients with stage II and stage III CRC were recruited for this study, including 379 patients with stage II and 607 patients with stage III disease. 357 (36.2%) patients suffered recurrences and 225 (22.8%) died by the date of the most recently scheduled follow-up. Table [1](#T1){ref-type="table"} summarizes the baseline characteristics of included patients. The mean age was 57.69 years with an SD of 12.18. There were more male patients than female patients, with a male/female ratio of 1.34.The median value of total bilirubin (TBIL), direct bilirubin (DBIL), indirect bilirubin (IDBIL) were 11.04 (range 2.70--66.50) μmol/l, 3.54 (range: 1.00--12.30) μmol/l, 7.50 (range: 1.70--54.20) μmol/l, respectively.

###### Baseline of patients with colorectal cancer treated with surgical resection

  Variable                  DBIL group                                
  ------------------------- ------------ ------ ----- ------ -------- -------
  Sex                                                        0.683    0.408
   Male                     326          56.0   237   58.7            
   Female                   256          44.0   167   41.3            
  Age                                                        0.492    0.483
   0                        324          55.7   234   57.9            
   \> 60                    258          44.3   170   42.1            
  Primary site                                               0.649    0.421
   Colon                    286          49.1   188   46.5            
   Rectum                   296          50.9   216   53.5            
  Grade                                                      0.201    0.905
   High/ Moderate           404          69.4   281   69.6            
   Poor/ Anaplastic         141          24.2   100   24.8            
   Unknown                  37           6.4    23    5.7             
  T stage                                                    2.870    0.238
   T1--2                    81           13.9   68    16.8            
   T3                       301          51.7   215   53.2            
   T4                       200          34.4   121   30.0            
  N stage                                                    14.934   0.001
   N0                       245          42.1   134   33.2            
   N1                       199          33.2   126   31.2            
   N2                       144          24.7   144   35.6            
  No. of LNs                                                 3.736    0.053
   \< 12                    157          27.0   132   32.7            
   ≥ 12                     425          73.0   272   67.3            
  Lymphovascular invasion                                    4.969    0.026
   Negative                 415          71.3   261   64.6            
   Positive                 617          28.7   143   35.4            
  Perineural invasion                                        0.230    0.632
   Negative                 464          79.7   317   78.5            
   Positive                 118          20.3   87    21.5            

Prognostic value of DBIL {#s2_2}
------------------------

We first treated TBIL, DBIL,IDBIL as a continuous variable, and only DBIL was validated as a significant prognostic factor by univariate cox rgression test for both OS and disease free survival (DFS) (*P* \< 0.05) (Table [2](#T2){ref-type="table"}). We then used X-tile program to determine the optimal cut-off values for DBIL in terms of OS and DFS, which happens to be 3.6 μmol/l for both OS and DFS (Figure [1](#F1){ref-type="fig"}). Patients were then divided into DBIL high (DBIL ≥ 3.60 μmol/l) and low group (DBIL \< 3.60 μmol/l) according to the optimal cutoff. Patients in high DBIL group had higher percentage of lymph node metastasis (N1 and N2 stage) and lymphovascular invasion as compared with those patients in DBIL low group (Table [1](#T1){ref-type="table"}).

###### Univariate cox rgression test of TBIL, DBIL,IDBIL on survival outcome in stage II and stage III CRC patients after radical resection

  Variable   HR      95% CI         *P* value
  ---------- ------- -------------- -----------
  **OS**                            
   TBIL      0.917   0.789--1.067   0.263
   DBIL      1.112   1.036--1.194   0.003
   IDBIL     0.906   0.738--1.111   0.342
  **DFS**                           
   TBIL      1.018   1.000--1.037   0.055
   DBIL      1.097   1.033--1.164   0.003
   IDBIL     1.017   0.992--1.044   0.182

![X-tile analyses of 5-year OS and DFS were performed using patients' data to determine the optimal cut-off value for DBIL\
The sample of CRC patients was equally divided into training and validation sets. X-tile plots of training sets are shown in the *left panels*, with plots of matched validation sets shown in the *smaller inset*. The optimal cut-off values highlighted by the *black circles* in *left panels* are shown in histograms of the entire cohort (*middle panels*), and Kaplan-Meier plots are displayed in *right panels*. *P* values were determined by using the cut-off values defined in training sets and applying them to validation sets. The optimal cut-off value for DBIL in terms of OS and DFS happens to be 3.6 μmol/l.](oncotarget-08-71138-g001){#F1}

Aside from DBIL, patients in elder group (*P* = 0.023), with poor differentiated caicinoma (*P* \< 0.001), with advanced T stage (*P* = 0.001) and N stage (*P* \< 0.001), presented with lymphovascular invasion (*P* \< 0.001) and perineural invasion (*P* = 0.001) shared a worse 5-year OS (Table [3](#T3){ref-type="table"}). In addition, patients with poor differentiated caicinoma (*P* \< 0.001), with advanced T stage (*P* \< 0.001) and N stage (*P* \< 0.001), with less than 12 lymph node retrieval (*P* = 0.005), presented with lymphovascular invasion (*P* \< 0.001) and perineural invasion (*P* \< 0.001) suffered a shorter 5-year DFS (Table [4](#T4){ref-type="table"}).

###### Univariate and multivariate survival analyses for evaluating the influence of serum direct bilirubin on OS in stage II and III colorectal cancer

  Variable                  5-year OS   Univariate analysis   Multivariate analysis                          
  ------------------------- ----------- --------------------- ----------------------- ---------------------- ----------
  Sex                                   0.388                 0.533                                          
   Male                     73.4%                                                                            
   Female                   74.9%                                                                            
  Age                                   5.170                 0.023                                          0.004
   \< 60                    76.9%                                                     Reference              
   ≥ 60                     71.0%                                                     1.493 (1.140--1.955)   
  Primarysite                           0.013                 0.911                                          
   Colon                    74.3%                                                                            
   Rectum                   73.8%                                                                            
  Grade                                 21.388                \< 0.001                                       0.267
   High/ Moderate           77.9%                                                     Reference              
   Poor/ Anaplastic         64.1%                                                     1.283 (0.942--1.747)   0.114
   Unknown                  69.6%                                                     1.214 (0.733-2.010)    0.452
  T Stage                               13.375                0.001                                          0.042
   T1--2                    86.1%                                                     Reference              
   T3                       73.2%                                                     1.744 (1.054--2.884)   0.030
   T4                       69.8%                                                     1.950 (1.159--3.280)   0.012
  N stage                               92.978                \< 0.001                                       \< 0.001
   N0                       88.0%                                                     Reference              
   N1                       75.3%                                                     1.944 (1.312--2.897)   0.001
   N2                       54.1%                                                     3.469 (2.318--5.190)   \< 0.001
  No. of LNs                            1.836                 0.175                                          
   \< 12                    70.9%                                                                            
   ≥ 12                     75.7%                                                                            
  Lymphovascular invasion               64.976                \< 0.001                                       0.003
   Negative                 82.0%                                                     Reference              
   Positive                 57.7%                                                     1.568 (1.163--2.112)   
  Perineural invasion                   11.873                0.001                                          0.899
   Negative                 77.0%                                                     Reference              
   Positive                 64.1%                                                     1.020 (0.747--1.393)   
  DBIL                                  9.213                 0.002                                          0.034
   Low                      77.0%                                                     Reference              
   High                     70.0%                                                     1.337 (1.022--1.748)   

NI: not included in the multivariate survival analysis.

###### Univariate and multivariate survival analyses for evaluating the influence of serum direct bilirubin on DFS in stage II and III colorectal cancer

  Variable                  5-year DFS   Univariate analysis   Multivariate analysis                          
  ------------------------- ------------ --------------------- ----------------------- ---------------------- ----------
  Sex                                    0.335                 0.563                                          
   Male                     61.3%                                                                             
   Female                   64.4%                                                                             
  Age                                    0.082                 0.774                                          
   \< 60                    63.6%                                                                             
   ≥ 60                     61.6%                                                                             
  Primarysite                            0.130                 0.719                                          
   Colon                    63.7%                                                                             
   Rectum                   61.0%                                                                             
  Grade                                  19.782                \< 0.001                                       0.345
   High/ Moderate           66.3%                                                      Reference              
   Poor/ Anaplastic         53.4%                                                      1.200 (0.923--1.562)   0.173
   Unknown                  56.7%                                                      1.208 (0.775--1.883)   0.405
  T Stage                                15.411                \< 0.001                                       0.002
   T1--2                    77.3%                                                      Reference              
   T3                       61.3%                                                      1.631 (1.099--2.422)   0.015
   T4                       57.7%                                                      2.049 (1.360--3.088)   0.001
  N stage                                112.864               \< 0.001                                       \< 0.001
   N0                       80.5%                                                      Reference              
   N1                       59.9%                                                      2.002 (1.471--2.727)   \< 0.001
   N2                       39.9%                                                      3.212 (2.322--4.443)   \< 0.001
  No. of LNs                             7.792                 0.005                                          0.004
   \< 12                    55.5%                                                      Reference              
   ≥ 12                     65.6%                                                      0.710 (0.563--0.897)   
  Lymphovascular invasion                46.655                \< 0.001                                       0.279
   Negative                 70.3%                                                      Reference              
   Positive                 46.4%                                                      1.150 (0.893--1.480)   
  Perineural invasion                    37.396                \< 0.001                                       0.010
   Negative                 67.0%                                                      Reference              
   Positive                 45.2%                                                      1.403 (1.086--1.811)   
  DBIL                                   10.250                0.001                                          0.018
   Low                      66.5%                                                      Reference              
   High                     57.1%                                                      1.312 (1.049--1.643)   

NI: not included in the multivariate survival analysis.

The variables significant in univariate log-rank test were incorported into multivariate cox regression analysis.The results confirmed that high DBIL level was an independently prognostic factor for both OS (HR:1.337, 95% CI:1.022--1.748, *P* = 0.034) and DFS (HR:1.312,95% CI: 1.049--1.643, *P* = 0.018) in patients with stage II and stage III CRC after surgical resection (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}).

Development and validation of nomograms for predicting prognosis of CRC patients {#s2_3}
--------------------------------------------------------------------------------

To predict the OS and DFS of patients with CRC, two nomograms were established by multivariate Cox regression model according to all significantly independent factors for OS and DFS (Figure [2A, 2B](#F2){ref-type="fig"}). Nomograms can be interpreted by summing up the points assigned to each variable, which is indicated at the top of scale. The total points can be converted to predicted 5-year probability of death and recurrence or metastasis for a patient in the lowest scale \[[@R6], [@R17]\]. The Harrell's c-indexes for OS and DFS prediction were 0.715 (95% CI: 0.683--0.748) and 0.704 (95% CI: 0.678--0.730), respectively. Calibration curves for two nomograms (Figure [2C, 2D](#F2){ref-type="fig"}) reveal no deviations from the reference line and no need of recalibration.

![Nomograms conveyed the results of prognostic models using clinicopathological characteristics and pretreatment inflammatory biomarkers to predict OS (A) and DFS (B) of patients with CRC\
Nomograms can be interpreted by summing up the points assigned to each variable, which is indicated at the top of scale. The total points can be converted to predicted 5-year probability of death and recurrence or metastasis for a patient in the lowest scale. The Harrell's c-indexes for OS and DFS prediction were 0.715 (95% CI: 0.683--0.748) and 0.704 (95% CI: 0.678--0.730), respectively. Calibration curves for 5-year OS (**C**) and 5-year DFS (**D**) using nomograms with clinicopathological characteristics and pretreatment inflammatory biomarkers are shown. The *x*-axis is nomogram-predicted probability of survival and *y*-axis is actual survival. The reference line is 45 degree and indicates perfect calibration.](oncotarget-08-71138-g002){#F2}

DISCUSSION {#s3}
==========

Distant metastasis and local recurrence remain main concerns in patients with CRC \[[@R6], [@R18]\]. Factors known to be associated with decreased survival would provide the ability to pre-select those patients who would benefit most from more aggressive treatments or intensive follow-up \[[@R19]\]. Pathologic stage is valuable for predicting prognosis in patients with CRC; however, survival outcome is quite different even in patients at same stage. Although helical computed tomography and positron emission tomography may help to detect metastasis after radical surgery, for the potential radiation harm, they cannot be repeated performed, and the cost is also very high. Some oncogene or tumor suppressors were also proposed as valuable predictors, but most of these biomarkers were only validated in relative small number of patients, and some of them may difficult to measure due to sophisticated and expensive laboratory techniques were required.Identification of a simple and cost-effective indicator for predicting patient prognosis is an important goal.

Bile acid is the end product of cholesterol breakdown, which takes place in hepatocytes, and there are three formations in peripheral blood, TBIL, DBIL and IDBIL. In this study, we demonstrated that pretreatment serum DBIL was an independently prognostic factor for both OS and DFS in stage II and stage III CRC patients after surgery. High DBIL level correlated with lymph node metastases and lymphovascular invasion. To illustrate the improvement of the DBIL on the prediction of CRC survival, we developed two nomogram for OS and DFS included the traditional prognostic factors (T stage, N stage, lymphovascular invasion, perineural invasion, et al.) and DBIL, and found the nomogram could give a well prediction for survival. Another strength of our study is that we first treated TBIL, DBIL, IDBIL as a continuous variable, and validated DBIL as a potential predictor for both OS and DFS, then we used X-tile program, a robust graphical tool verified by Yale University \[[@R20]\], to verify the optimum cut-off values for DBIL. In fact, cut-off values of DBIL vary in different studies. For example, Gao et al. \[[@R8]\] used the thresholds 2.6 μmol/l as cutoff to classified the DBIL, while Li et al. \[[@R14]\] adopted 3.45 μmol/l as optimal cutoff in non-small-cell lung cancer, which value is quite close to our present study.It should be noted that in some studies used TBIL as main concern for survival analysis \[[@R15], [@R16], [@R21]\].TBIL consists of both DBIL and IDBIL, which may cause confuse.

As described in the background section, some epidemiological researches demonstrated that elevated serum bilirubin concentration was negatively correlated with the risk of CRC, whereas others found no significant association \[[@R13], [@R22]\]. However, different from their studies, our present study was designed to investigate the relationship between serum bilirubin and survival outcome in CRC. We found that increased serum DBIL was associated with a higher percentage of lymph node metastases and lymphovascular invasion, thus cause poor survival outcome, our conclusion also consisted with previous published articles \[[@R8]\]. Serum bilirubin levels also negatively correlated with response of metastatic CRC to irinotecan-based chemotherapy \[[@R23]\]. We hypothesis that serum bilirubin may play dual role in CRC tumorigenesis and progression.

Undeniably, there were some limitations in our study. First, we only included patients with stage II and III in the present study. Those metastatic patients and stage I CRC were not included. Thus the results cannot represent all patients with CRC. Second, only pretreatment DBIL was included in the study, and we cannot known the changes of DBIL in the course of therapy, and whether the changes may impact the survival outcome of CRC patients. Third, our study was complemented in two center cohorts included only Chinese patients. Although internal validation was performed to prevent over-interpretation of current data, it would be better is external validation can be carried out to verify whether our findings are universally applicable \[[@R24]\].

In conclusion, our retrospective study demonstrates that increasing pretreatment DBIL significantly correlated with poor outcomes in stage II and stage III CRC patients after surgical resection. This biomarker was directly derived from routine laboratory test of liver function, and can be easily applied in the clinical setting.

MATERIALS AND METHODS {#s4}
=====================

Study population {#s4_1}
----------------

The study included 986 patients with CRC who received surgical resection between January 2005 and December 2010. The inclusion criteria were: (1) age \> 18 years old; (2) pathological diagnosis of CRC adenocarcinoma; (3) without distant metastasis (M1); (4) underwent surgical resection; (5) without preoperative anti-tumor therapy; (6) CRC was the only one primary or first of more than one primary; (7) laboratory tests were obtained before surgery with defined value; (8) information on OS and DFS available. The exclusion criteria were as follows: (1) patients diagnosed with hereditary non-polyposis CRC and familial adenomatous polyposis; (2) patients with hepatobiliary disease (including malignancy, gallstones, cirrhosis, hepatitis, or alcoholic liver disease, et al.) or hematological disease which may affect the bilirubin measurement. (3) patients that did not have complete clinical and pathological data; (4) patients with stage I CRC were also excluded from the study for the survival outcome were extremely good for them. 5-Fu or 5-FU derivate agents based adjuvant chemotherapy was recommended for stage II patients with high-risk characteristics and all stage III patients within 3 to 4 weeks after surgery. Ethical approval was obtained from the Ethical Committee and Institutional Review Board of The Fifth People's Hospital of Shanghai, Fudan University.

The following parameters were included in the analysis: age, gender, tumor differentiation, tumor stage, node stage, the number of retrieval lymph nodes and positive lymph node count, lymphovascular invasion, perineural invasion, TBIL, DBIL, and IDBIL. All patients were restaged according to the 7th edition of the American Joint Committee on Cancer TNM classification. Patients with stages II of high risk and all stage III tumor received adjuvant chemotherapy with fluoropyrimidine-based regimens.

Statistical analysis {#s4_2}
--------------------

Statistical evaluation was conducted with SPSS 22.0 (SPSS Inc., Chicago, IL, USA) and R 3.1.2 software (Institute for Statistics and Mathematics, Vienna, Austria). X-tile 3.6.1 \[[@R25]\] (Yale University, New Haven, CT, USA) was used to determine the optimal cut-off value for DBIL. The 5-year OS and DFS were estimated by the Kaplan-Meier method, and the difference of variables was compared using log-rank tests. Univariate analysis was used to examine the association between various prognostic predictors and OS, DFS. Significant prognostic predictors associated with OS and DFS were included to perform multivariate analyses by using the Cox proportional hazards model. *P* \< 0.05 was considered statistically significant. All confidence intervals (CIs) were stated at the 95% confidence level.

Nomograms for possible prognostic factors associated with OS and DFS were established by R software, and the model performance for predicting outcome was evaluated by Harrell's concordance index (c-index) \[[@R26], [@R27]\]. In addition to measuring discriminative capacity by c-index, each model was evaluated with calibration curve in which predicted outcomes versus observed outcomes are graphically depicted, which made it possible to conduct further comparison of accuracy in estimating prognosis.
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